Lipocine Inc. (LPCN)

Market price: $1.53

1 valuation method

• EV / Revenue: $1.66 to $2.56 (midpoint $2.11)

How each method works

EV / Revenue: $1.66 to $2.56 (midpoint $2.11)

Values the whole business at a peer multiple of sales — used when earnings are thin, volatile, or not yet meaningful, so revenue is the most reliable yardstick.

How it’s calculated

We multiply the company's last-twelve-month revenue by the range of EV/Revenue multiples its peer group trades at, subtract net debt and any minority interests or preferred stock ranking ahead of common shareholders, and divide by shares outstanding for a per-share range.

Why it fits this industry

When profits are thin, volatile, or still to come, revenue is the most dependable figure a company reports — this method values the business on the scale of what it actually sells.

Reading this bar

The bar is the per-share value range this method implies: a conservative low, a central estimate, and an optimistic high. If the current price sits below the bar, the market is pricing the shares below what this method's inputs suggest; if it sits above, the market is pricing them higher. No single bar is a verdict — methods disagree for good reasons, so read the whole field together. A pound of revenue is worth more at a high margin than a low one, so the peer group here is narrowed to companies earning a similar margin wherever enough of them exist. Where too few do, the bar falls back to the wider group and is the bluntest of the multiples — weigh it alongside the earnings-based bars.

EV / Revenue = (5.54/7.92/10.30)× revenue 1,569,460 ≈ 8,701,086.24/12,430,123.20/16,159,160.16 (enterprise_value); enterprise_value -> per share: equity (13,680,516.24/17,409,553.20/21,138,590.16) / 8,244,253 shares [EV bridge: minus net debt -4,979,430]

5 methods not shown

• EV / EBITDA: EBITDA is non-positive — an EBITDA multiple yields no meaningful enterprise value (loss-making at the EBITDA line)
• EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
• P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
• P / B: the market prices this company far outside its sector's P / B range (its own multiple is 0.57 vs a sector band of 5.75–10.69) — a sector-average bar would be misleading here, so it is withheld
• DCF (FCFF): DCF input(s) unavailable (capex) — cannot build FCFF

Pre-profit company — earnings-based methods not meaningful.

Limited data — fewer than three valuation methods could be formed for this company; showing every method we can stand behind.